Statins
Triple lipid-lowering therapy after ACS cuts LDL-C 59% but raises Lp(a) 91%, Indian cohort of 345 (J Clin Lipidol 2026)
Original title: Changes in lipoprotein(a) and their association with LDL-C in patients with ACS treated with triple oral lipid-lowering therapy
Retrospective study of 345 statin-naive Indian patients with acute coronary syndrome (ACS) treated with rosuvastatin (20-40 mg), ezetimibe (10 mg) and bempedoic acid (180 mg) for 1 month after PCI, assessing 1-month changes in Lp(a) and LDL-C. Mean LDL-C fell 59.1%, while mean Lp(a) rose 91% (42.2 to 80.5 mg/dL, p<0.001). LDL-C targets of below 50 and below 55 mg/dL were reached in 68.9% and 78.6% of patients respectively. Baseline Lp(a) independently predicted failure to reach the LDL-C goal (adjusted OR 0.97, 95% CI 0.96-0.98, p<0.001), while diabetes increased the likelihood of reaching target (adjusted OR 2.69, 95% CI 1.36-5.61, p=0.006); Lp(a) change and LDL-C goal achievement were strongly and significantly inversely correlated (rho=-0.38). The authors interpret the Lp(a) rise as a likely acute-phase response and suggest baseline Lp(a) testing could help refine residual-risk assessment and guide use of emerging Lp(a)-targeted treatments.
Original abstract
Background: Lipoprotein(a) [Lp(a)] is a well-established, genetically determined risk factor for atherosclerotic cardiovascular disease, but its short-term response to aggressive lipid-lowering therapy after acute coronary syndrome (ACS) remains unclear.
Objective: To evaluate 1-month changes in Lp(a) and assess whether baseline Lp(a) levels are associated with low-density lipoprotein cholesterol (LDL-C) goal achievement in statin-naive ACS patients undergoing triple oral lipid-lowering therapy.
Methods: We retrospectively analyzed 345 patients with ACS treated with rosuvastatin (20-40 mg), ezetimibe (10 mg), and bempedoic acid (180 mg) for 1 month after percutaneous coronary intervention. Lp(a) and LDL-C were measured at baseline and 1 month. Multivariable logistic regression identified predictors of achieving the LDL-C goal (<50 mg/dL).
Results: Despite a 59.1 ± 17.3% reduction in the mean LDL-C, the average Lp(a) increased by 91% (from 42.2 ± 39.2 mg/dL to 80.5 ± 66.3 mg/dL, P < .001). LDL-C targets of <50 mg/dL and <55 mg/dL were achieved in 68.9% and 78.6% patients, respectively. Baseline Lp(a) independently predicted failure to reach LDL-C goals (adjusted odds ratio [OR] 0.97; 95% CI 0.96-0.98; P < 0.001), while diabetes mellitus increased the likelihood of achieving targets (adjusted OR 2.69; 95% CI 1.36-5.61; P = .006). A strong inverse relationship was observed between Lp(a) change and LDL-C goal achievement (ρ = -0.38, P < 10⁻¹²).
Conclusion: In Indian patients with ACS, aggressive triple oral lipid-lowering therapy quickly reduces LDL-C, while being accompanied by a substantial rise in Lp(a) levels, likely reflecting an acute-phase response. Baseline Lp(a) may independently limit LDL-C target attainment. Early Lp(a) testing may improve residual risk assessment and help guide the use of emerging Lp(a)-focused treatments.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 17 August 2026. Methods.